This study explores how well **tirzepatide** works when added to **ixekizumab** treatment for people with **moderate-to-severe plaque psoriasis (PsO)** and who are also **obese or overweight**. Psoriasis is a skin condition that causes red, itchy patches. **Ixekizumab** is a medication already used for treating PsO, and **tirzepatide** is a new drug being tested. Participants need to have a body mass index (BMI) of 27 or more and at least one weight-related health issue, like high blood pressure or type 2 diabetes. The study lasts up to 12 months. To join, you should have started using ixekizumab about 3 months ago. You can't join if you've used tirzepatide before or are in another study.

• The study lasts for up to 12 months.
• Participants need to have started using ixekizumab about 3 months ago.
• You can't join if you've used tirzepatide before.